This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AptarGroup CEO Discusses Q4 2011 Results - Earnings Call Transcript

We will post a replay of this conference call on our website as we've done in the past. AptarGroup undertakes no obligation to update the forward-looking information. And at this time, I'd like to turn the conference over to Steve Hagge.

Steve Hagge

Thanks, Matt, and good morning, everyone. I'm pleased to report that 2011 was another record year for AptarGroup. I'd like to recognize the hard work of our talented employees have put into our business this past year. Their dedication is the reason for our success and why we're the leader in our industry.

As we look back on 2011 it was an exciting year. We began reporting the results of our newly aligned business segments. Each of our three segments reported sales growth over the prior year. We entered new market categories. We expanded our global presence. And we enhanced shareholder value.

I'll briefly recap the full year performance of our segments and then comment on the fourth quarter. I'll begin with our Beauty and Home segment, which completed the year with organic sales growth of 6%. Demand for our products from the fragrance, cosmetic and household markets remained strong throughout much of the year, while demand from our personal care market also increased over the prior year. However, profit margins were pressured due to a competitive market, under utilized capacity towards the end of the year, increased professional fees and our overall product mix.

Our Pharma segment had an outstanding year with strong organic sales growth of 10%. We entered a new category in the consumer healthcare segment with our preservative free Ophthalmic dispenser and we saw continued growth in our prescription segment, particularly from the strong demand from the generic market in the US. Our Pharma segment's profitability remained strong throughout the year reflecting our ability to help our customers grow in this highly specialized and regulated industry.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.20 -1.00%
FB $118.09 0.56%
GOOG $695.87 0.51%
TSLA $222.00 -4.40%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.61 -99.30 -0.56%
S&P 500 2,052.99 -10.38 -0.50%
NASDAQ 4,731.4740 -31.75 -0.67%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs